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A 10-year-old male (LLS) with homozygous SS, had been reg-ntroduction
rythrovirus B19 (B19V), a member of Parvoviridae family,
enus Erythrovirus, is a small non-enveloped DNA virus, with
pproximately 5000 nucleotides. There are three distinct geno-
ypes (1, 2 and 3) with genotype 1 being the most prevalent in
he world.1
B19V infection is associated with many  clinical manifes-
ations, depending on the immunological and hematological
tatus of the patient. The virus has tropism for bone marrow
rythroblasts, on which it exerts a cytotoxic effect and deter-
ines temporary suspension of erythropoiesis, leading to a
ransient episode of red cell aplasia.2
In sickle cell anemia (SCA) patients, B19V is known to be
he etiologic agent of transient aplastic crises.3 Many other
omplications may be associated with B19V infection, such as
cute splenic sequestration4,5 and acute chest syndrome.6The diagnosis of B19V infection can be achieved by detec-
ing anti-B19V antibodies or by molecular biology techniques
hat allow the identiﬁcation of the viral DNA using direct
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pen  access article under the CC BY-NC-ND license (http://creativecomhybridization or polymerase chain reaction (PCR), or even by
direct identiﬁcation of the virus by electron microscopy.7
The B19V seroprevalence increases with age and can vary
from 2 to 15% in under ﬁve-year-old children, 15 to 60% for
individuals aged six to 19 years, between 30 and 60% in adults,
and up to 85% in the elderly population,8 both in developed
and developing countries.9
In a study of 278 children with sickle cell disease (SS or
S0-thalassemia, median age 5.8 years; range: 0.9–12.3 years),
it has been shown that past or recent viral infection occurred
in 29.5% (95% conﬁdence interval: 24.1–34.9%).5 This report
describes the clinical course and the laboratory tests of two
siblings selected to participate in that cohort.
Case  reports-200 Belo Horizonte, MG, Brazil.
ularly followed up in the outpatient clinic of the Blood Center
in Belo Horizonte since the diagnosis of SCA by the Newborn
Screening Program of Minas Gerais, Brazil. He was admitted to
 e Terapia Celular. Published by Elsevier Editora Ltda. This is an
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Table 1 – Blood counts during transient aplastic crises in
two siblings with sickle cell anemia.
Sibling 1 Sibling 2
Age at aplastic crisis (years) 10 12
Gender M M
Genotype SS SS
At admission (Day 1)
Hemoglobin (g/dL) 5.4 3.4
Hematocrit (%) 16 11.3
Leukocytes (×109/L) 3.5 9.2
Neutrophils (%) 86 54
Reticulocytes (%) Not done* Not done*
Platelets (×109/L) “Normal” 301
Day 2
Hemoglobin (g/dL) 6.0 4.5
Hematocrit (%) 19.9 14
Leukocytes (×109/L) 5.2 6.6
Neutrophils (%) 58 38
Reticulocytes (%) 0.3 0.1
Platelets (×109/L) 240 282
Day 4
Hemoglobin (g/dL) 5.6 Not done
Hematocrit (%) 17.4 Not done
Leukocytes (×109/L) 7.2 Not done
Neutrophils (%) 16 Not done
Red cell transfusion 10 mL/kg
(Days 2 and 5)
10 mL/kg
(Days 1 and 3)
Hospital discharge Day 6 Day 4
∗ Reticulocyte counts are not part of the routine tests performed in
the hospital laboratory; counts on the second day of admission
Conﬂicts  of  interestwere performed in the Hemominas laboratory.
the emergency room of the João Paulo II Children’s Hospital in
Belo Horizonte with a history of back pain, headache and fever
of up to 38.7 ◦C for two days prior to admission. Physical exam-
ination revealed a heart rate of 90 bpm and liver 3 cm below
the costal margin, spleen not palpable and anicteric. On the
day of admission, he had two episodes of vomiting, and slurry
evacuation. Respiratory symptoms were absent. Low back pain
subsided the same day and the headache became intermit-
tent. The vomiting and diarrhea receded the following day.
Ampicillin was initiated upon admission but was discontinued
the next day, since there was no fever or other symptoms of
bacterial infection, and radiographic evaluation showed that
chest and face were normal. Blood counts are shown in Table 1.
Before the hospital admission, this patient had been ran-
domly selected for a research study aiming to investigate
B19V infection in children with SCA, as previously mentioned.
His serum sample had been drawn 16 months before the
transient bone marrow hypoplasia event. In that sample no
anti-B19V antibodies (IgG or IgM class – Biotrin, Ireland) had
been detected, nor had viral DNA by quantitative PCR (in-
house test). One year after the episode of erythroid hypoplasia
a new serum sample of the patient was drawn, as recom-
mended by the study. This sample was positive for anti-B19V
IgG antibodies and negative for IgM antibodies and viral DNA.
A 12-year-old male (ALS), sibling of “Case 1”, was also
regularly followed up in the outpatient clinic at Fundac¸ão
Hemominas since the diagnosis of SCA in the newborn period. 2 0 1 6;3  8(3):271–273
The patient was admitted to the same hospital 13 days after
his brother. Before hospital admission, his symptoms had
been headache and runny nose without fever for one week.
They subsided spontaneously, but after three days, he pre-
sented a headache associated with vomiting and a fever peak
of 38.7 ◦C. Ibuprofen was prescribed at a government health
clinic and the symptoms receded. One day prior to hospital
admission, he again had headaches associated with pain in
the cervical spine and vomiting. His mother reported that the
degree of her son’s pallor had clearly increased. At admission,
he was slightly dehydrated, severely pale and mildly jaun-
diced. Heart and respiratory rates were 110 bpm and 26 breaths
per minute, respectively; blood pressure was 110/70 mm Hg,
his liver was 7 cm from the costal margin, and spleen was
not palpable. Blood counts are also shown in Table 1. B19V
DNA was detected by real time PCR, and typed as genotype 1
(Figure 1).
Comments
B19V infection causes signiﬁcant morbidity in children with
SCA. Although studies have been reported on the subject,
there are still limited data on the epidemiology of this infec-
tion, as well as the complications associated with it.
Intrafamilial transmission of B19V infection is considered
an important event for viral spread. It has been demonstrated
that the single risk factor for B19V seroconversion in a child
was the presence of siblings with a recent B19V infection (odds
ratio: 2.97; 95% conﬁdence interval: 1.29–6.81).2 The rate of sec-
ondary infection in families with two or more children with
sickle cell disease was 56.3%.
It is known that the vast majority of children with SCA
who have serologic evidence of previous B19V infection had
not developed symptomatic aplastic crisis,10 as was also
demonstrated by our recent cohort study.5 Different degrees
of baseline hemoglobin concentration, virus load, virus geno-
types or other unknown factors could explain this observation,
although genotype and virus load were the same in both chil-
dren during a nosocomial B19V outbreak, one child with very
severe manifestations and the other with an asymptomatic
course.11 It is interesting to note that the diagnosis of acute
transient aplastic crisis in children with SCA who  are being
treated with hydroxyurea is not different to those who  are not
being treated with hydroxyurea. The clinical course was very
similar, relapsing or chronic B19V infection was not observed,
and the production of B19V-speciﬁc immunoglobulins was
apparently normal.12
In conclusion, our report suggests that host immunologic
background may play a signiﬁcant role in the pathogene-
sis and clinical course of aplastic crises secondary to B19V
infection, as both brothers showed life-threatening clinical
manifestations. Since serological and molecular tests are not
always available, the reticulocyte count is essential when tran-
sient bone marrow hypoplasia caused by B19V is suspected, so
that proper supportive care can be immediately started.The authors declare no conﬂicts of interest.
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Figure 1 – In-house real time polymerase chain reaction assay using speciﬁc hydrolysis probes to detect erythrovirus B19
genotypes 1, 2, and 3. Positive ampliﬁcation for genotype 1 (black line) was detected in Case 2. The horizontal green line
represents the threshold for positivity. Intersection of this line with the black line (arrow) indicates the cycle ampliﬁcation
threshold (Ct) value. The early Ct = 12 points for a high virus load. Fluorescent signals below the threshold indicate negative
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